Comparative Pharmacology
Head-to-head clinical analysis: GYNOREST versus NORETHINDRONE AND ETHINYL ESTRADIOL 7 14.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNOREST versus NORETHINDRONE AND ETHINYL ESTRADIOL 7 14.
GYNOREST vs NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gynorest (dydrogesterone) is a synthetic progestogen that binds to the progesterone receptor with high selectivity, inducing conformational changes that promote transcription of progesterone-responsive genes. It has no androgenic, estrogenic, or corticosteroid activity, and does not inhibit ovulation.
Norethindrone is a progestin that suppresses gonadotropin release, preventing ovulation. Ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary axis, further inhibiting ovulation. The combination also alters cervical mucus and endometrial lining to impede fertilization and implantation.
100 mg orally twice daily for 5-10 days or 300 mg orally once daily for 6-12 days.
One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg) orally once daily for 21 days (7 active tablets of norethindrone 0.5 mg/ethinyl estradiol 35 mcg followed by 14 active tablets of norethindrone 1 mg/ethinyl estradiol 35 mcg). Start on day 1 of menstrual cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 16-20 hours; supports twice-daily dosing for maintenance of therapeutic levels.
Norethindrone: 8-11 hours; Ethinyl estradiol: 17-27 hours. Achieves steady state within 5-10 days, permitting once-daily dosing.
Renal: 50-80% as metabolites; Fecal: 20-50% as metabolites; Biliary excretion contributes to fecal elimination.
Norethindrone: ~50% renal, ~50% fecal; Ethinyl estradiol: ~50% renal, ~50% fecal, with enterohepatic circulation.
Category C
Category D/X
Progestin
Progestin